Stockscreener 앱 받기
4.49
0.22%
0.02
전일 마감가:
$4.47
열려 있는:
$4.36
하루 거래량:
4,946
Relative Volume:
0.03
시가총액:
$49.16M
수익:
-
순이익/손실:
$-19.25M
주가수익비율:
-2.5225
EPS:
-1.78
순현금흐름:
$-17.87M
1주 성능:
-1.97%
1개월 성능:
+18.21%
6개월 성능:
+3.46%
1년 성능:
+0.90%
1일 변동 폭
$4.33
$4.5518
1주일 범위
$4.1046
$4.75
52주 변동 폭
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
명칭
Lantern Pharma Inc
전화
972-277-1136
주소
1920 MCKINNEY AVENUE, DALLAS, TX
LTRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
4.5518 | 47.95M | 0 | -19.25M | -17.87M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.00 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.39 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.44 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
667.01 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.57 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-07 | 개시 | H.C. Wainwright | Buy |
Lantern Pharma Inc 주식(LTRN)의 최신 뉴스
Lantern Pharma Launches AI Tool predictBBB.ai with 94% Accuracy for Blood-Brain Barrier Drug Development - citybuzz -
RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26 - Tri-City Herald
Will Lantern Pharma Inc. price bounce be sustainableJuly 2025 Summary & Safe Capital Preservation Plans - Newser
What does recent volatility data suggest for Lantern Pharma Inc.Market Activity Recap & Accurate Technical Buy Alerts - Newser
Key metrics from Lantern Pharma Inc.’s quarterly data2025 Growth vs Value & Weekly Chart Analysis and Trade Guides - Newser
Is Lantern Pharma Inc. meeting your algorithmic filter criteriaWeekly Stock Recap & High Return Stock Watch Alerts - Newser
Will a bounce in Lantern Pharma Inc. offer an exitTrend Reversal & Daily Technical Forecast Reports - Newser
Can swing trading help recover from Lantern Pharma Inc. lossesTreasury Yields & Smart Investment Allocation Insights - Newser
Published on: 2025-08-17 03:16:20 - Newser
Published on: 2025-08-17 02:12:31 - Newser
What institutional flow reveals about Lantern Pharma Inc.2025 Year in Review & Free Community Consensus Stock Picks - Newser
Analyzing Lantern Pharma Inc. with multi timeframe chartsTrade Volume Report & Verified Entry Point Signals - Newser
Can volume confirm reversal in Lantern Pharma Inc.2025 Fundamental Recap & Capital Protection Trade Alerts - Newser
Price momentum metrics for Lantern Pharma Inc. explainedMarket Movers & Safe Entry Point Alerts - Newser
Applying Wyckoff theory to Lantern Pharma Inc. stockInsider Buying & Free Verified High Yield Trade Plans - Newser
Advanced analytics toolkit walkthrough for Lantern Pharma Inc.2025 Top Decliners & Technical Confirmation Trade Alerts - Newser
Sectors Driving Future Growth for Lantern Pharma Inc. Stock2025 Breakouts & Breakdowns & Safe Entry Zone Tips - Newser
Does Lantern Pharma Inc. have strong EBITDA margins2025 EndofYear Setup & Weekly Hot Stock Watchlists - newsimpact.co.kr
Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN
Lantern Pharma Inc. Recovery Likely Here’s What Data ShowsJuly 2025 Outlook & Daily Profit Focused Screening - sundaytimes.kr
Lantern Pharma shares fall 6.72% intraday despite positive clinical trial results. - AInvest
What is Lantern Pharma Inc.’s book value per share2025 Analyst Calls & Long Hold Capital Preservation Plans - newsyoung.net
Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses In Multiple Trials - Barchart.com
Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses in Multiple Trials - The Globe and Mail
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates - BioSpace
Lantern Pharma Narrows Loss in Q2 - The Motley Fool
Lantern Pharma Narrows Loss in Q2 - Nasdaq
Lantern Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates | LTRN Stock News - GuruFocus
What data driven models say about Lantern Pharma Inc.’s futureWeekly Trend Watch with Market Signals - Newser
Short Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Rises By 109.5% - MarketBeat
Automated trading signals detected on Lantern Pharma Inc.Free Entry Points For Growing Stocks - Newser
Os Therapies Incorporated shares rise 1.14% intraday after Lantern Pharma's subsidiary cleared IND application for GBM trial. - AInvest
Lantern Pharma Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Lantern Pharma Inc. Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule - citybuzz -
Lantern Pharma (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations - Barchart.com
Lantern Pharma (LTRN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Lantern Pharma Announces Release of Advanced AI Module for Blood-Brain Barrier Permeability Prediction - AI Insider
Nerdy Inc. shares rise 1.78% after-hours following Lantern Pharma's FDA clearance for GBM trial. - AInvest
How Lantern Pharma Inc. stock performs during market volatilityDaily Stock Forecast Powered by AI Tools - Newser
Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial - Barchart.com
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed - openPR.com
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Dnatrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuticals - Menafn
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | DNAtrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuticals - Barchart.com
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial | LTRN Stock News - GuruFocus
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U - GuruFocus
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial - Business Wire
Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy - Barchart.com
Lantern Pharma completes Japanese enrolment for lung cancer drug trial - Mugglehead Magazine
Lantern Pharma schließt japanische Rekrutierung für Lungenkrebsmedikamentstudie ab - Mugglehead Magazine
Real Time Chart Alerts Flash Bullish on Lantern Pharma Inc.Swing Trade Plans Emphasize Risk Management - metal.it
Lantern Pharma Inc (LTRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lantern Pharma Inc 주식 (LTRN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
1.17%
0.36%
자본화:
|
볼륨(24시간):